Stockscreener 앱 받기
1.97
1.55%
0.03
시간 외 거래:
1.97
전일 마감가:
$1.94
열려 있는:
$1.92
하루 거래량:
253.51K
Relative Volume:
0.61
시가총액:
$192.54M
수익:
$32.38M
순이익/손실:
$-21.64M
주가수익비율:
-7.8268
EPS:
-0.2517
순현금흐름:
$-13.78M
1주 성능:
+1.03%
1개월 성능:
+2.07%
6개월 성능:
-12.44%
1년 성능:
-11.66%
1일 변동 폭
$1.92
$2.00
1주일 범위
$1.91
$2.10
52주 변동 폭
$1.70
$3.59
Stereotaxis Inc Stock (STXS) Company Profile
명칭
Stereotaxis Inc
전화
314-678-6100
주소
4320 Forest Park Avenue, Suite 100, St. Louis, MO
Compare STXS vs ISRG, BDX, ALC, MDLN, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
STXS
Stereotaxis Inc
|
1.97 | 189.61M | 32.38M | -21.64M | -13.78M | -0.2517 |
ISRG
Intuitive Surgical Inc
|
402.30 | 146.01B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
144.43 | 40.04B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
64.28 | 32.04B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
33.19 | 30.23B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
182.82 | 27.04B | 5.54B | 1.52B | 1.74B | 10.37 |
Stereotaxis Inc Stock (STXS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-16 | 개시 | Citizens JMP | Mkt Outperform |
| 2024-01-10 | 개시 | ROTH MKM | Buy |
| 2022-07-12 | 개시 | Aegis Capital | Buy |
| 2022-06-23 | 개시 | B. Riley Securities | Buy |
| 2022-01-05 | 개시 | Craig Hallum | Buy |
| 2022-01-05 | 개시 | Loop Capital | Buy |
| 2021-05-26 | 개시 | Piper Sandler | Overweight |
| 2020-09-08 | 개시 | Northland Capital | Outperform |
| 2020-04-09 | 개시 | Cowen | Outperform |
| 2020-04-07 | 개시 | Lake Street | Buy |
모두보기
Stereotaxis Inc 주식(STXS)의 최신 뉴스
STXS News | STEREOTAXIS INC (NYSEARCA:STXS) - ChartMill
Stereotaxis stock up on first US MAGIC procedures post approval - MSN
Stereotaxis (STXS) Edges Higher: Navigating the Robotics Sector with Modest GainsVolatility Term Structure - Newser
Stereotaxis Emerges as Notable Oversold Play in AI Sector with Over 120 Percent Implied Upside - HarianBasis.co
Analysts See 124.7% Upside In Stereotaxis (STXS); Find Out Why - Insider Monkey
Stereotaxis Inc. (STXS) Edges Higher as Stock Tests Key Resistance Near $2.02Shared Buy Zones - Newser
STXS Q1 2026 Earnings: Larger-Than-Expected Loss as Company Continues Strategic TransitionROA Comparison - Newser
5 Most Oversold AI Stocks to Buy According to Analysts - Insider Monkey
Stereotaxis Q1 earnings call highlights - MSN
Stereotaxis to acquire Robocath for up to $45M - MSN
Stereotaxis Q1 Earnings Call Highlights - sharewise.com
Stereotaxis shareholders elect directors and approve key proposals at annual meeting - Investing.com India
Stereotaxis, Inc. touts robotic technology to address physician burnout and improve patient care - Traders Union
Lagoda Investment discloses 4.5% stake in Stereotaxis (STXS) - Stock Titan
Stereotaxis Q4 Loss Narrows, Revenue Rises - Moomoo
Stereotaxis (NYSE: STXS) holders back board, auditor and executive pay - Stock Titan
Stereotaxis Inc. (STXS) reports Q1 loss, lags revenue estimates - MSN
Stereotaxis reports early traction for new products as Robocath acquisition advances - The Business Journals
Stereotaxis, Inc. 1Q 2026: Revenue $6.29M, EPS $(0.06) — 10-Q Summary - TradingView
Stereotaxis (STXS) posts Q1 2026 loss and plans $20M Robocath acquisition - Stock Titan
STXS Reiterated by Piper Sandler -- Price Target Lowered to $3.5 - GuruFocus
Lake Street Maintains Stereotaxis(STXS.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Stereotaxis, Inc. (AMEX:STXS) Q1 2026 Earnings Call Transcript - Insider Monkey
Stereotaxis expects annual revenue to surpass $40M with Q3 and Q4 above $10M as MAGiC and Synchrony ramp - MSN
Stereotaxis Inc (STXS) Q1 2026 Earnings Call Highlights: Navigat - GuruFocus
Stereotaxis Inc (STXS) Q1 2026 Earnings Call Highlights: Navigating Regulatory Wins and Revenue ... By GuruFocus - Investing.com Canada
Stereotaxis (STXS) Q1 2026 Loss Near US$6 Million Tests Bullish Margin Narrative - Sahm
Stereotaxis, Inc. (STXS) Reports Strong Q1 2026 Earnings and Gro - GuruFocus
Earnings call transcript: Stereotaxis Q1 2026 misses forecasts, stock dips - Investing.com India
Is Stereotaxis (STXS) Still 23.2% Undervalued After Q1 2026? EPS - GuruFocus
STXS: Regulatory wins and new product launches drive optimism for double-digit revenue growth in 2026 - TradingView
Earnings call transcript: Stereotaxis Q1 2026 misses forecasts, stock dips By Investing.com - Investing.com Nigeria
STXS: Transition to new robotic and catheter platforms drives optimism for double-digit growth in 2026 - TradingView
Stereotaxis Inc. (STXS) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Stereotaxis Q1 2026 Earnings Call Transcript - Benzinga
Stereotaxis Inc (NYSEARCA:STXS) Slides 6% After Q1 Revenue Miss Despite Narrower-Than-Expected Loss - ChartMill
Stereotaxis Q1 Loss Narrows, Revenue Falls - marketscreener.com
Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates - The Manila Times
Surgical robotics provider Stereotaxis' Q1 revenue misses analyst estimates - TradingView
STXS: FDA approvals and Robocath deal set stage for growth despite Q1 revenue decline - TradingView
Stereotaxis (NYSE: STXS) Q1 revenue dips as FDA clearances and Robocath deal advance - Stock Titan
Stereotaxis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
TradingKey - TradingKey
Stereotaxis Q1 2026 earnings preview - MSN
TD Cowen Maintains Stereotaxis(STXS.US) With Buy Rating, Maintains Target Price $5 - Moomoo
STXS Stereotaxis revenue jumps 20 percent year-over-year to 32.4 million, profitability challenges persist.Market Perform - newser.com
STXS to acquire Robocath to lead in endovascular robotics market - MSN
Stereotaxis Inc (STXS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.52%
1.16%
자본화:
|
볼륨(24시간):